Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Genscript sells tools and services that help scientists study genes and develop new medicines, and it also owns a cell therapy business working on cancer treatments.
Genscript is a life sciences company that sells the everyday tools and services scientists need to study genes and proteins. If a lab wants a specific piece of DNA made to order, a custom antibody, or a protein produced for experiments, Genscript is one of the places it can buy that. The company also runs a contract research arm that handles bigger pieces of drug discovery work for other companies.
The business has three main parts. The first is the life science products and services unit — gene synthesis, cloning, antibodies, and related lab supplies sold to universities, research institutes, and drug companies. The second is a biologics development arm that helps biopharma companies manufacture biologic drugs, the medicines made from living cells rather than chemical synthesis. The third, and the one that grabs the most attention, is a cell therapy business built around CAR-T technology — engineering a patient's own immune cells to attack cancer. That cell therapy work sits mainly in a subsidiary called Legend Biotech, which is publicly traded on its own in the US under the ticker Legend Biotech. Genscript retains a controlling stake in it. Legend's lead product, Carvykti, is a CAR-T therapy for multiple myeloma developed with Johnson & Johnson, and it is the piece of the Genscript story with the biggest potential upside and the biggest cash burn. Cell therapy is expensive to develop and manufacture, so this unit has weighed on profits even as the science is promising.
Genscript makes money in two very different ways: steady, recurring fees from selling research tools and services to thousands of labs, and the much lumpier, higher-risk bet on cell therapy paying off through drug sales and royalties. The tools business is the reliable engine; the cell therapy arm is the lottery ticket that could be worth far more than the rest of the company combined. The company is headquartered in Nanjing, China, and has grown from a small custom-gene shop into a global player that competes with larger life science suppliers. The main risk is straightforward: if Carvykti and the rest of the cell therapy pipeline succeed, the payoff is enormous, but if development or commercialization stumbles, the losses are real and ongoing.
Saved answer · last researched 15 Nov 2026